Maraviroc
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2007
- First approval year
- 2007
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Maraviroc
- Molecular weight
- 513.68
- Structure (SMILES)
- Cc1nnc(C(C)C)n1[C@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1
- celsentri
- Celsentri
- selzentry
- Selzentry
- ART intensification (maraviroc)
- art intensification maraviroc
- Celsentri®
- CELSENTRI® Tablets
- maraviroc
- Maraviroc
- Maraviroc (5 days)
- Maraviroc (Celsentri)
- Maraviroc (MVC)
- Maraviroc (Part 1)
- Maraviroc (Part 2)
- maraviroc (Selzentry)
- Maraviroc 150 MG
- Maraviroc 300 mg
- maraviroc endo
- Maraviroc, endo-
- rel maraviroc
- Rel-maraviroc
- Selzentry
- uk 427 857
- uk 427857
- Uk-427,857
- UK-427857
- ATC classification codes
- J05AX09
Sources for recorded values
- ChEMBL ID
- CHEMBL256907
- InChIKey
- GSNHKUDZZFZSJB-QUMGSSFMSA-N
- RxNorm IDs (RxCUI)
- 620216
- FDA ingredient codes (UNII)
- A3C7SRV8DV
- 376348-65-1
- 2414315-81-2
- Applicant
- VIIV HLTHCARE
- Approval date
- 6 Aug 2007
- Application number
- NDA022128
- Status
- Authorised
- Status date
- 18 Sept 2007
- Authorisation date
- 18 Sept 2007
- Approved indications
- Celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable
- Product number
- EMEA/H/C/000811
- Authorisation holder
- ViiV Healthcare B.V.
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- HIV Infections
European medicines record
- Patents
- 0
- Designations
- 3
- First in class
- Yes
- Fast track
- Yes
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- Yes
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- maraviroc
- Type
- Synthetic organic
- Drug name stem
- -vir-
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Action
- Antagonist
- Action type
- Antagonist
- Target
- CCR5
- Gene symbol
- CCR5
- Protein identifier
- P51681
- Median affinity
- 8.1
- Affinity units
- pIC50
- Primary target
- Yes
- Mechanism
- C-C chemokine receptor type 5 antagonist
- Action type
- Antagonist
- Target
- C-C chemokine receptor type 5
- Protein identifier
- P51681
Open Targets mechanisms
- Mechanism
- C-C chemokine receptor type 5 antagonist
- Action type
- Antagonist
- Target
- C-C chemokine receptor type 5
DrugCentral mechanisms
- Action type
- Antagonist
- Gene symbol
- CCR5
- Protein identifier
- P51681
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Leukemia, Lymphocytic, Chronic, B-Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000095
- Subject identifier
- D015451
- Condition
- HIV Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000180
- Subject identifier
- D015658
- Condition
- Hodgkin Disease
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000339
- Subject identifier
- D015464
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Sarcoma, Kaposi
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000558
- Subject identifier
- D012514
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition
- Stroke
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000712
- Subject identifier
- D020521
- Condition
- Virus Diseases
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000763
- Subject identifier
- D014777
- Condition
- HIV Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Acquired Immunodeficiency Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000765
- Subject identifier
- D000163
- Condition
- AIDS Dementia Complex
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002608
- Subject identifier
- D015526
- Condition
- Hypertriglyceridemia
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004211
- Subject identifier
- D015228
- Condition
- Cognitive Dysfunction
- Highest recorded phase
- 2
- Condition identifier
- HP:0100543
- Subject identifier
- D060825
- Condition
- Graft vs Host Disease
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0013730
- Subject identifier
- D006086
- Condition
- Lymphoma, Follicular
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0018906
- Subject identifier
- D008224
- Condition
- Hematologic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0044881
- Subject identifier
- D019337
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000180
- Condition identifier
- EFO_0000180
- Highest recorded phase
- 4
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000558
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000685
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000712
- Condition identifier
- EFO_0000763
- Condition identifier
- EFO_0000764
- Condition identifier
- EFO_0000765
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002608
- Condition identifier
- EFO_0004211
- Highest recorded phase
- 1
- Condition identifier
- EFO_0007948
- Highest recorded phase
- 2
- Condition identifier
- HP_0001297
- Highest recorded phase
- 2
- Condition identifier
- HP_0001397
- Highest recorded phase
- 2
- Condition identifier
- HP_0001513
- Highest recorded phase
- 1
- Condition identifier
- HP_0100543
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004648
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004790
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004995
- Condition identifier
- MONDO_0005002
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005055
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005091
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005108
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005109
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 1
And 10 more, listed on the interactive page.
Warnings
- Warning
- Black Box Warning
- Effect
- hepatotoxicity
Open Targets warnings
- Warning
- Black Box Warning
- Effect
- hepatotoxicity
- Country
- United States
- Event
- abortion spontaneous
- Reports
- 18
- Reporting signal score
- 14.626
- Event
- acute myocardial infarction
- Reports
- 15
- Reporting signal score
- 15.2234
- Event
- aids dementia complex
- Reports
- 3
- Reporting signal score
- 14.9616
- Event
- anal cancer
- Reports
- 7
- Reporting signal score
- 26.6617
- Event
- anogenital dysplasia
- Reports
- 6
- Reporting signal score
- 30.6367
- Event
- blood hiv rna increased
- Reports
- 11
- Reporting signal score
- 37.8986
- Event
- cd4 lymphocytes decreased
- Reports
- 7
- Reporting signal score
- 18.0323
- Event
- congenital bladder anomaly
- Reports
- 4
- Reporting signal score
- 18.5616
- Event
- congenital renal disorder
- Reports
- 6
- Reporting signal score
- 26.9267
- Event
- congenital ureteric anomaly
- Reports
- 4
- Reporting signal score
- 20.5797
- Event
- congenital vesicoureteric reflux
- Reports
- 4
- Reporting signal score
- 21.3271
- Event
- csf test abnormal
- Reports
- 10
- Reporting signal score
- 45.0144
- Event
- dermatitis exfoliative
- Reports
- 9
- Reporting signal score
- 15.6562
- Event
- drug resistance
- Reports
- 33
- Reporting signal score
- 59.5304
- Event
- enanthema
- Reports
- 8
- Reporting signal score
- 31.6801
- Event
- generalised anxiety disorder
- Reports
- 9
- Reporting signal score
- 31.961
- Event
- hepatic failure
- Reports
- 11
- Reporting signal score
- 13.2035
- Event
- hodgkin's disease
- Reports
- 27
- Reporting signal score
- 93.4705
- Event
- hyperbilirubinaemia
- Reports
- 20
- Reporting signal score
- 42.3203
- Event
- hyperlipidaemia
- Reports
- 12
- Reporting signal score
- 17.7771
- Event
- immune reconstitution inflammatory syndrome
- Reports
- 9
- Reporting signal score
- 16.3072
- Event
- immune reconstitution syndrome
- Reports
- 6
- Reporting signal score
- 17.3008
- Event
- kaposi's sarcoma
- Reports
- 9
- Reporting signal score
- 21.5087
- Event
- kidney enlargement
- Reports
- 7
- Reporting signal score
- 25.3969
- Event
- lipodystrophy acquired
- Reports
- 16
- Reporting signal score
- 53.2507
And 16 more, listed on the interactive page.
- NCT00098293
- NCT00795444
- NCT00993148
- NCT01345630
- NCT01348308
- NCT01400412
- NCT02486510
- NCT00098306
- NCT00098722
- NCT00098748
- NCT00426660
- NCT00478231
- NCT00496782
- NCT00537394
- NCT00624195
- NCT00634959
- NCT00643643
- NCT00703586
- NCT00717067
- NCT00719823
- NCT00735072
- NCT00771823
- NCT00791700
- NCT00808002
- NCT00821535
And 60 more, listed on the interactive page.
- Dose
- 150 mg or 300 mg or 600 mg
- Route
- Oral
- How often
- Twice daily
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 1
- Polar surface area
- 63.05
- Calculated partition coefficient (ALogP)
- 5.95
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 8
- Heavy atoms
- 37
- Molecular formula
- C29H41F2N5O
- Natural product
- No
These details could not be displayed.
Related records
Trials (200)
- A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven Biologicals
- A Compassionate Access Protocol For Those Patients Who Have Completed A4001029
- A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies
- A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc
- A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants
- A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients.
- A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID
- A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients
- A Open-label, Drug-Drug Interaction With Maraviroc (DDI)
- A Phase 1 Study to Assess the Safety and Effects of Single and Multiple Doses of KS101 in Healthy Volunteers
- A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability
- A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
- A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy
- A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients
- A Safety and Pharmacokinetic Study for Dapivirine and Maraviroc Gel in Belgium
- A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis
- A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma
- A Study Evaluating the Efficacy of Glucocorticoids in Patients With Pre-ACLF-HBV
- A Study in Healthy Men to Test How BI 1265162 is Taken up and Processed by the Body
- A Study in Patients With Advanced Breast Cancer
Approved for (2)
In development for (16)
- AIDS Phase 3
- AIDS dementia complex Phase 2
- B-cell chronic lymphocytic leukemia Phase 2
- Chronic myeloid leukemia Phase 2
- Chronic obstructive pulmonary disease Phase 3
- COVID-19 Phase 2
- Diffuse large B-cell lymphoma Phase 2
- Follicular lymphoma Phase 2
- Graft versus host disease Phase 2
- Hematopoietic and lymphoid cell neoplasm Phase 2
- Hodgkins lymphoma Phase 2
- Hypertriglyceridemia Phase 1
- Kaposi's sarcoma Phase 2
- Myelodysplastic syndrome Phase 2
- Rheumatoid arthritis Phase 2
- Stroke disorder Phase 2
Other linked conditions (1)
Targets (1)
- CCR5 C-C chemokine receptor type 5 antagonist